| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Diaby V et al. | Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. | 2017 | Breast Cancer Res. Treat. | pmid:28840424 |
| Sabbaghi M et al. | Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. | 2017 | Clin. Cancer Res. | pmid:28821558 |
| He X et al. | Inflammatory Monocytes Loading Protease-Sensitive Nanoparticles Enable Lung Metastasis Targeting and Intelligent Drug Release for Anti-Metastasis Therapy. | 2017 | Nano Lett. | pmid:28758755 |
| Shafaee MN et al. | Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. | 2017 | J Oncol Pract | pmid:28678590 |
| Liu Y et al. | LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). | 2017 | J Pharm Biomed Anal | pmid:28131055 |
| Venkatesa P | NICE recommends routine NHS funding for Kadcyla. | 2017 | Lancet Oncol. | pmid:28648556 |
| Daniels B et al. | Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. | 2017 | BMJ Open | pmid:28119394 |
| Kosmin M et al. | Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. | 2017 | Target Oncol | pmid:28110417 |
| Andreev J et al. | Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. | 2017 | Mol. Cancer Ther. | pmid:28108597 |
| Schönfeld K et al. | Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. | 2017 | J Hematol Oncol | pmid:28077160 |
| van Boxtel W et al. | Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma. | 2017 | Oral Oncol. | pmid:28673692 |
| Ait-Oudhia S et al. | A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. | 2017 | AAPS J | pmid:28646408 |
| Loebrich S et al. | Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. | 2017 | AAPS J | pmid:28534292 |
| Meng H et al. | A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy. | 2017 | Macromol Biosci | pmid:28464449 |
| Singh AP and Shah DK | Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). | 2017 | AAPS J | pmid:28374319 |
| Martin LP et al. | Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. | 2017 | Gynecol. Oncol. | pmid:28843653 |
| Wang H et al. | Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. | 2017 | Cancer Sci. | pmid:28388007 |
| Lambert JM and Morris CQ | Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. | 2017 | Adv Ther | pmid:28361465 |
| Socinski MA et al. | Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. | 2017 | Clin Lung Cancer | pmid:28341109 |
| Carvajal-Hausdorf DE et al. | Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. | 2017 | Gynecol. Oncol. | pmid:28196634 |